JAKi Market Experience and MOA

ACR=American College of Rheumatology; DMARD=disease-modifying antirheumatic drug; Dx=diagnosis; EULAR=European League Against Rheumatism; JAK=Janus kinase; JAKi=Janus kinase inhibitor; MOA=mechanism of action; MTX=methotrexate; PsA=psoriatic arthritis; RA=rheumatoid arthritis; Rx=prescription; UC=ulcerative colitis.
References: 1. XELJANZ/XELJANZ XR [prescribing information]. New York, NY: Pfizer Inc.; December 2019. 2. Data on file. Pfizer Inc., New York, NY. 3. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68(1):1-25. 4. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960-977. 5. Hodge JA, Kawabata TT, Krishnaswami S, et al. The mechanism of action of tofacitinib – an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(2):318-328.